{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:09:27Z","timestamp":1794362967067,"version":"4.9.0"},"reference-count":23,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed\/refractory diffuse large B-cell lymphoma. From May 2019 onwards, 47 relapsed\/refractory diffuse large Bcell lymphoma patients, \u226570 years underwent lymphopharesis in three Israeli centers. Elderly (n=41, mean age 76.2 years) and young (n=41, mean age 55.4 years) patients were matched based on ECOG performance status and lactose dehydrogenase levels. There were no differences in CD4\/CD8 ratio (P=0.94), %CD4 naive (P=0.92), %CD8 naive (P=0.44) and exhaustion markers (both HLA-DR and PD-1) between CAR-T cell products in both cohorts. Forty-one elderly patients (87%) received CAR-T cell infusion. There were no differences in the incidence of grade \u22653 cytokine-release-syndrome (P=0.29), grade\u22653 neurotoxicity (P=0.54), and duration of hospitalization (P=0.55) between elderly and younger patients. There was no difference in median D7-CAR-T cell expansion (P=0.145). Response rates were similar between the two groups (complete response 46% and partial response 17% in the elderly group, P=0.337). Non-relapse mortality at 1 and 3 months was 0 in both groups. With a median follow-up of 7 months (range, 1.3-17.2 months), 6- and 12-months progression-free and overall survival in elderly patients were 39% and 32%, and 74% and 69%, respectively. EORTC QLQ-C30 questionnaires, obtained at 1 month, showed worsening of disability and cancer-related-symptoms in elderly versus younger patients. We conclude that outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration. Longer rehabilitation therapy is essential to improve disabilities and long-term symptoms.<\/jats:p>","DOI":"10.3324\/haematol.2021.278288","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T14:54:22Z","timestamp":1625756062000},"page":"1111-1118","source":"Crossref","is-referenced-by-count":72,"title":["Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients \u2013 a matched control multicenter cohort study"],"prefix":"10.3324","volume":"107","author":[{"given":"Ron","family":"Ram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Grisariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Shargian-Alon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaeli","family":"Bar-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Sarid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Glait-Santar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigi","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"35539","doi-asserted-by":"crossref","unstructured":"Hedstrom G, Hagberg O, Jerkeman M, Enblad G. The impact of age on survival of diffuse large B-cell lymphoma - a populationbased study. Acta Oncol. 2015; 54(6):916-923.","DOI":"10.3109\/0284186X.2014.978367"},{"key":"35540","doi-asserted-by":"crossref","unstructured":"Adiyaman SC, Alacacioglu A, Ersen Danyeli A. Prognostic factors in elderly patients with diffuse large B-cell lymphoma and their treatment results. Turk J Haematol. 2019; 36(2):81-87.","DOI":"10.4274\/tjh.galenos.2019.0218.0219"},{"key":"35541","doi-asserted-by":"crossref","unstructured":"Lazarus HM, Carreras J, Boudreau C. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008; 14(12):1323-1333.","DOI":"10.1016\/j.bbmt.2008.09.008"},{"key":"35542","doi-asserted-by":"crossref","unstructured":"Shah NN, Ahn KW, Litovich C. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018; 2(8):933-940.","DOI":"10.1182\/bloodadvances.2018018531"},{"key":"35543","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"35544","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"35545","doi-asserted-by":"crossref","unstructured":"Yakoub-Agha I, Chabannon C, Bader P. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020; 105(2):297-316.","DOI":"10.3324\/haematol.2019.229781"},{"key":"35546","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020; 135(23):2106-2109.","DOI":"10.1182\/blood.2019004162"},{"key":"35547","doi-asserted-by":"crossref","unstructured":"Gajra A, Zettler ME, Phillips EG. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy. 2020; 12(14):1077-1082.","DOI":"10.2217\/imt-2020-0161"},{"key":"35548","doi-asserted-by":"crossref","unstructured":"Lin RJ, Lobaugh SM, Pennisi M. Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed\/refractory large b-cell lymphoma. Haematologica. 2020; 106(1):255-258.","DOI":"10.3324\/haematol.2019.243246"},{"key":"35549","doi-asserted-by":"crossref","unstructured":"Zettler ME, Feinberg BA, Phillips EG, Klink AJ, Mehta S, Gajra A. Real-world adverse events associated with CAR T-cell therapy among adults age \u226565 years. J Geriatr Oncol. 2021; 12(2):239-242.","DOI":"10.1016\/j.jgo.2020.07.006"},{"key":"35550","doi-asserted-by":"crossref","unstructured":"Maertens J, Marchetti O, Herbrecht R. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2011; 46(5):709-718.","DOI":"10.1038\/bmt.2010.175"},{"key":"35551","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"35552","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Jain MD, Feng L. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"35553","doi-asserted-by":"crossref","unstructured":"Vercellino L, Di Blasi R, Kanoun S. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(22):5607-5615.","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"35554","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"35555","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"35556","doi-asserted-by":"crossref","unstructured":"Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol. 2018; 182(5):633-643.","DOI":"10.1111\/bjh.15412"},{"key":"35557","doi-asserted-by":"crossref","unstructured":"Greinix HT, Attarbaschi A, Girschikofsky M. Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. memo. 2020; 13(1):27-31.","DOI":"10.1007\/s12254-020-00582-4"},{"key":"35558","doi-asserted-by":"crossref","unstructured":"Kuhnl A, Roddie C, Martinez-Cibrian N. Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England. Blood. 2019; 134(Suppl 1):S767.","DOI":"10.1182\/blood-2019-124177"},{"key":"35559","doi-asserted-by":"crossref","unstructured":"Paillassa J, Di Blasi R, Chevret S. CD19 CAR T-cell therapy in patients with relapse\/refractory DLBCL: retrospective analysis of the eligibility criteria. Blood. 2019; 134(Suppl 1):S2887.","DOI":"10.1182\/blood-2019-129532"},{"key":"35560","doi-asserted-by":"crossref","unstructured":"Riedell PA, Walling C, Nastoupil LJ. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Blood. 2019; 134(Suppl 1):s1599.","DOI":"10.1182\/blood-2019-127490"},{"key":"35561","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Waller EK, Jaeger U. Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(4):629-637.","DOI":"10.1182\/bloodadvances.2019001026"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278288\/73513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278288\/74398","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10324\/73513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:57Z","timestamp":1794045597000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278288","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}